NYSEAMERICAN:ATNMActinium Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Actinium Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.59 -0.01 (-1.67 %) (As of 08/4/2020 04:00 PM ET) Add Compare Share Today's Range$0.58Now: $0.59▼$0.6150-Day Range N/A52-Week Range$0.16Now: $0.59▼$0.65Volume16.42 million shsAverage Volume10.79 million shsMarket Capitalization$233.14 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingActinium Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.25, Actinium Pharmaceuticals has a potential upside of 281.4% from its current price of $0.59.Amount of Analyst CoverageActinium Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.2 Community Rank Outperform VotesActinium Pharmaceuticals has received 322 “outperform” votes. (Add your “outperform” vote.)Underperform VotesActinium Pharmaceuticals has received 189 “underperform” votes. (Add your “underperform” vote.)Community SentimentActinium Pharmaceuticals has received 63.01% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote “Outperform” if you believe ATNM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATNM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldActinium Pharmaceuticals does not currently pay a dividend.Dividend GrowthActinium Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.34 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:ATNM Previous SymbolAMEX:ATNM CUSIPN/A CIKN/A Webwww.actiniumpharmaceuticals.com Phone+1-646-6773875Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees30 Outstanding Shares395,155,000Market Cap$233.14 million Next Earnings Date8/14/2020 (Estimated) OptionableOptionable $0.59 -0.01 (-1.67 %) (As of 08/4/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ATNM News and Ratings via Email Sign-up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Actinium Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Actinium Pharmaceuticals. When is Actinium Pharmaceuticals' next earnings date? Actinium Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Actinium Pharmaceuticals. How were Actinium Pharmaceuticals' earnings last quarter? Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) released its earnings results on Monday, June, 29th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.02) by $0.01. View Actinium Pharmaceuticals' earnings history. What price target have analysts set for ATNM? 3 brokers have issued 12-month price targets for Actinium Pharmaceuticals' shares. Their forecasts range from $1.50 to $3.00. On average, they anticipate Actinium Pharmaceuticals' share price to reach $2.25 in the next twelve months. This suggests a possible upside of 281.4% from the stock's current price. View analysts' price targets for Actinium Pharmaceuticals. Has Actinium Pharmaceuticals been receiving favorable news coverage? Press coverage about ATNM stock has trended somewhat negative on Wednesday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Actinium Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the near future. View the latest news about Actinium Pharmaceuticals. Who are some of Actinium Pharmaceuticals' key competitors? Some companies that are related to Actinium Pharmaceuticals include iShares Diversified Alternatives Trust (ALT), Altimmune (ALT), PureTech Health (PRTC), Trillium Therapeutics (TRIL), Oxford BioMedica (OXB), Nkarta (ANNX), Aptose Biosciences (APS), SIGA Technologies (SIGA), Ibio (IBIO), CEL-SCI (CVM), Paradigm Biopharmaceuticals (PAR), Biotest (BIO), IMV (IMV), Neptune Wellness Solutions (NEPT) and Inventiva (IVA). View all competitors. What other stocks do shareholders of Actinium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Opko Health (OPK), TransEnterix (TRXC), Tandem Diabetes Care (TNDM), Cancer Genetics (CGIX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Align Technology (ALGN). Who are Actinium Pharmaceuticals' key executives? Actinium Pharmaceuticals' management team includes the following people: Mr. Sandesh C. Seth, Chairman & CEO (Age 55)Mr. Steven O'Loughlin BS, Principal Financial & Accounting Officer (Age 33)Dr. Dale L. Ludwig Ph.D., Chief Scientific Officer (Age 57)Dr. Mark S. Berger, Chief Medical Officer (Age 64)Mr. Anil Kapur, Chief Commercial Officer (Age 50) What is Actinium Pharmaceuticals' stock symbol? Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM." Who are Actinium Pharmaceuticals' major shareholders? Actinium Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include UBS Group AG (0.02%). Company insiders that own Actinium Pharmaceuticals stock include Dale L Ludwig and Steve O'loughlin. View institutional ownership trends for Actinium Pharmaceuticals. Which institutional investors are selling Actinium Pharmaceuticals stock? ATNM stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View insider buying and selling activity for Actinium Pharmaceuticals. How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Actinium Pharmaceuticals' stock price today? One share of ATNM stock can currently be purchased for approximately $0.59. How big of a company is Actinium Pharmaceuticals? Actinium Pharmaceuticals has a market capitalization of $233.14 million. Actinium Pharmaceuticals employs 30 workers across the globe. What is Actinium Pharmaceuticals' official website? The official website for Actinium Pharmaceuticals is www.actiniumpharmaceuticals.com. How can I contact Actinium Pharmaceuticals? Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875. This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
